This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged >= 40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days.
Follow-up took place after two weeks and after one, two and three months. Primary [visual analogue scale (VAS), Western Ontario and McMaster Universities (WOMAC Index)] and secondary outcomes variables, assessed at weeks two, four, eight and 12, were KOA pain intensity measured by quadruple visual analogue scales in the target knee, the WOMAC total score index, patient's and investigator's global assessments of disease activity, joint assessment, use of rescue medication (ibuprofen 400 mg tablets) and assessment of Quality of Life index (SF-36 Questionnaire).
Safety and tolerability were also evaluated. Clear improvement was observed in both joint pain and symptoms in patients with KOA treated with EHC (Colatech (R)) and significant differences were observed.
Mean reductions from baseline for EHC 10 g daily and GS 1.5 g, respectively, were KOA pain intensity reduction in the target knee for Colatech (R) (p<0.05): WOMAC index decrease <= 15 points at the last visit (day 90) for Colatech (R) in 16 patients (34.04%) (p<0.05) and for glucosamine in six patients (13.04%); total score index for painful joints: Colatech (R) 1.6 (p<0.05) and glucosamine 1.8; total score index for swollen joints: Colatech (R) 0.5 (p<0.05) and glucosamine 0.7; patient's global assessment of efficacy as the sum of improvement good + ideal: 80.8% for Colatech (R) and 46.6% for glucosamine (p<0.05). EHC (Colatech (R)) showed superior improvement over GS in the SF-36 Questionnaire in the Physical Health Index (42.0 for Colatech and 40.0 for glucosamine).
The incidence of adverse events was similar in both groups. Both EHC and GS were well tolerated.